Molecular testing in thyroid cancer: BRAF mutation status and mortality

JAMA

Volumn 309, Issue 14, 2013, Pages 1529-1530

  Cappola, Anne R ^a   Mandel, Susan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

BRAF GENE; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DISTANT METASTASIS; EDITORIAL; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; ONCOGENE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; THYROID CANCER; THYROID PAPILLARY CARCINOMA;

EID: 84875931932     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.3620     Document Type: Editorial

References (7)

1. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801-3807.
2. National Cancer Institute. SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed March 12, 2013.
3. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
4. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA . 2013; 309(14):1493-1501.
5. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97(12):4559-4570.
6. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-762. (Pubitemid 350294294)
7. Howell GM, Carty SE, Armstrong MJ, et al. Both BRAF V600E mutation and older age (≥65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 2011;18(13):3566-3571.